Jerica Bobo
Primary Care · Romney, WVNPI 1659979011
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations.
Across 132 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$461
- AstraZeneca$331
- Novo Nordisk$237
- Lilly USA, LLC$235
- Amgen$114
- Boehringer Ingelheim$96
- plus $560 from 16 others
What the payments were for
- Food & beverage$2,01999%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,034 in reported general payments places this provider in the 80th percentile of 43 primary care providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $58,684 |
| FarxigaDapagliflozin Propanediol | 39 | $34,704 |
| VraylarCariprazine Hcl | 11 | $15,655 |
| JanuviaSitagliptin Phosphate | 14 | $12,500 |
| XareltoRivaroxaban | 16 | $11,546 |
| MounjaroTirzepatide | 11 | $11,270 |
| JardianceEmpagliflozin | 11 | $10,222 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $10,002 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 47 | $2,015 |
| Divalproex Sodium | 14 | $1,153 |
| Rosuvastatin Calcium | 82 | $1,092 |
| Ventolin HfaAlbuterol Sulfate | 13 | $946 |
| Potassium Chloride | 46 | $828 |
| Levothyroxine Sodium | 56 | $612 |
| Omeprazole | 68 | $565 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $237 | $58,68446 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $331 | $44,70653 claims |
| AbbVieVraylar | $461 | $15,65511 claims |
| Johnson & JohnsonXarelto | $45 | $11,54616 claims |
| Lilly USA, LLCMounjaro | $235 | $11,27011 claims |
| Boehringer IngelheimJardiance | $96 | $10,22211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 43 primary care providers in West Virginia.
Other primary care in Romney
- Amanda WakimWheeling$169K
- Brenda HashemBerkeley Springs$8K
- Brenda DennisGlen Dale$6K
- Molly WhiteCharleston$5K
- Richard SutherlandMartinsburg$4K
- Kayla MeadeHuntington$3K
- Crystal Clark-CrookshanksSummersville$3K
- Jessica FrankeGlen Dale$2K
- Alisa EllisonHinton$2K
- Amber BellMorgantown$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.